Brownstein Hyatt Farber Schreck is pleased to announce the addition of Ryan Waterman as a shareholder in its San Diego office. Waterman’s practice focuses on land use, CEQA/NEPA environmental review, and water and natural resource issues. Well known for his expertise in permitting a wide range of complex projects, including renewable solar and wind energy, mixed use, and commercial projects, Waterman also counsels clients on compliance with Clean Water Act permitting, including California’s new Industrial Storm Water permit. More >>

Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C. announced that Antony Nash has joined the firm as a Member in the Litigation Practice. He is based in the firm’s San Diego office. Prior to joining Mintz Levin Mr. Nash was a partner with McKenna, Long & Aldridge. More >>

Continuing the expansion of its Intellectual Property Practice and life sciences capabilities, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C. announced that Kenneth E. Jenkins has joined the firm as a Member in San Diego. He comes to Mintz Levin from Kilpatrick Townsend & Stockton, where he served as Managing Partner of the San Diego office. More >>

Cooley is advising Volcano Corp on its $1.2 billion sale to Royal Philips NV. The transaction, subject to regulatory approval, is expected to close in the first quarter of 2015. More >>

Cooley advised Isis Pharmaceuticals, Inc. on its Rule 144A offering of $500 million aggregate principal amount of convertible senior notes due 2021. The initial purchasers have purchased $15 million aggregate principal amount of convertible notes. More >>

Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for viral diseases, announced on September 30, 2014 a definitive agreement with Johnson & Johnson whereby Alios will be acquired for approximately $1.75 billion in cash payable upon closing of the transaction. The transaction has been approved by the boards of directors of both companies. More >>

Cooley is advising Ambit Biosciences on its agreement to be acquired by Daiichi Sankyo Company, Ltd. for approximately $315 million on a fully diluted basis. In addition to the upfront cash payment, each Ambit Biosciences stockholder will receive one Contingent Value Right (CVR), entitling the holder to receive an additional cash payment of up to $4.50 for each share they own if certain commercialization related milestones are achieved. The total transaction is valued at up to $410 million on a fully diluted basis. More >>

Cooley LLP announced today that it advised Horizon Pharma, Inc. on the completion of its acquisition of Vidara Therapeutics International plc. In connection with the acquisition, Horizon and Vidara have combined to form parent company Horizon Pharma plc, which is incorporated in Ireland. Concurrently with the acquisition, Horizon entered into a five-year $300 million term loan facility and related uncommitted facilities. More >>